For patients with DMD, the main therapeutic objective is to reconstruct the muscle stem cell pool containing the myostatin receptors, so as to restore the presence of myostatin expressing muscle fibers and recover muscle function (Shimizu-Motohashi et al., 2019). This evidence concerns the gene MSTN and Duchenne muscular dystrophy.